Last reviewed · How we verify

NCT01770886: UE2343

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral UE2343 in Healthy Subjects

Completed Phase 1 Last updated 16 July 2013
What this trial tests

Phase 1 trial testing UE2343 in Healthy in 48 participants. Completed in 1 July 2013.

Timeline
1 January 2013
Primary endpoint
1 July 2013
1 July 2013

Quick facts

Lead sponsorUniversity of Edinburgh
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment48
Start date1 January 2013
Primary completion1 July 2013
Estimated completion1 July 2013
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Edinburgh

Who can join

Adults 18 to 65, any sex, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

A randomised, double-blind, placebo-controlled, phase I study in healthy subjects. Safety, pharmacokinetic and pharmacodynamic data will be collected.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other University of Edinburgh trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01770886.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing